Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Earnings

News

Guidance

Health Care

Small Cap

Movers

Trading Ideas

General

FLGT

Fulgent Genetics Inc (NASDAQ: FLGT) reported Q2 sales of $68 million, beating the consensus estimate of $62.68 million.&lt;

Why Is Fulgent Genetics Stock Moving Higher Today?

Penny Stocks

HOTH

Why Fulgent Genetics Shares Are Trading Higher Today

Biotech

ABCL

ADGI

AGIO

ARYD

AXNX

BMRN

CDNA

CDXS

CLNN

COLL

EDIT

FOLD

GTHX

ICUI

IOVA

LMAT

LUNG

MGNX

MMSI

MRNA

NTRA

NVTA

ORPH

OTIC

PCRX

SAGE

SGMO

SILK

TMDX

TVTX

VCEL

VNDA

YMAB

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company

Fulgent Genetics Inc

Press Releases

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Fulgent Reports Second Quarter 2024 Financial Results

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Fulgent to Participate in Upcoming Conferences

Fulgent Reports Third Quarter 2024 Financial Results

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Accolade

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

InnovAge Holding

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

National Research Corporation - Common Stock

National Research

Nutex Health

OPKO Health

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

Premier

Pennant Gr

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Talkspace

Piper Sandler

Credit Suisse

Raymond James

Comments

Fulgent Genetics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga